212 related articles for article (PubMed ID: 10456621)
41. Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators.
Feinberg WM; Cornell ES; Nightingale SD; Pearce LA; Tracy RP; Hart RG; Bovill EG
Stroke; 1997 Jun; 28(6):1101-6. PubMed ID: 9183333
[TBL] [Abstract][Full Text] [Related]
42. Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators.
Bounameaux H; Ehringer H; Gast A; Hulting J; Rasche H; Rapold HJ; Reber G; Tschopp TB
Thromb Haemost; 1999 Apr; 81(4):498-501. PubMed ID: 10235427
[TBL] [Abstract][Full Text] [Related]
43. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.
Tanaka KA; Szlam F; Dickneite G; Levy JH
Thromb Res; 2008; 122(1):117-23. PubMed ID: 17977586
[TBL] [Abstract][Full Text] [Related]
44. Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin.
Gerotziafas GT; Dupont C; Spyropoulos AC; Hatmi M; Samama MM; Kiskinis D; Elalamy I
Thromb Haemost; 2009 Jul; 102(1):42-8. PubMed ID: 19572066
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis.
Ikhlaque N; Seshadri V; Kathula S; Baumann MA
Am J Hematol; 2006 Jun; 81(6):420-2. PubMed ID: 16680743
[TBL] [Abstract][Full Text] [Related]
46. A comparative study of prothrombin complex concentrates and fresh-frozen plasma for warfarin reversal under static and flow conditions.
Ogawa S; Szlam F; Ohnishi T; Molinaro RJ; Hosokawa K; Tanaka KA
Thromb Haemost; 2011 Dec; 106(6):1215-23. PubMed ID: 22071880
[TBL] [Abstract][Full Text] [Related]
47. Abrupt versus gradual withdrawal of vitamin K antagonist treatment in patients with venous thromboembolic disease: assessment of hypercoagulability and clinical outcome.
de Groot MR; Njo TL; van Marwijk Kooy M; Büller HR
Clin Lab; 2000; 46(11-12):575-81. PubMed ID: 11109505
[TBL] [Abstract][Full Text] [Related]
48. Coagulant activity during one year after bioprosthetic aortic valve replacement.
Imagawa H; Ryugo M; Shikata F; Nakata T; Nagashima M; Kawachi K
Interact Cardiovasc Thorac Surg; 2009 Apr; 8(4):417-20. PubMed ID: 19141491
[TBL] [Abstract][Full Text] [Related]
49. Heparin cofactor II: an acute phase reactant in patients with deep vein thrombosis.
Toulon P; Vitoux JF; Fiessinger JN; Sicard D; Aiach M
Blood Coagul Fibrinolysis; 1991 Jun; 2(3):435-9. PubMed ID: 1718466
[TBL] [Abstract][Full Text] [Related]
50. Prothrombin fragment F1+2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer.
Gadducci A; Marrai R; Baicchi U; Gagetti O; Facchini V; Genazzani AR
Gynecol Oncol; 1996 May; 61(2):215-7. PubMed ID: 8626135
[TBL] [Abstract][Full Text] [Related]
51. Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin.
Szlam F; Luan D; Bolliger D; Szlam AD; Levy JH; Varner JD; Tanaka KA
Thromb Res; 2010 May; 125(5):432-7. PubMed ID: 20004955
[TBL] [Abstract][Full Text] [Related]
52. Effects of warfarin on markers of hypercoagulability in patients with heart failure.
Jafri SM; Mammen EF; Masura J; Goldstein S
Am Heart J; 1997 Jul; 134(1):27-36. PubMed ID: 9266780
[TBL] [Abstract][Full Text] [Related]
53. Anticoagulation of a patient with hypertrophic cardiomyopathy and factor VII deficiency.
Davidson SJ; Turner N; Tillyer L
Blood Coagul Fibrinolysis; 2010 Oct; 21(7):707-8. PubMed ID: 20885134
[TBL] [Abstract][Full Text] [Related]
54. Audit of anticoagulant therapy of pulmonary embolus, deep vein thrombosis and thrombophlebitis.
Meinhold JM; Reale EO; Miller WA
Am J Hosp Pharm; 1979 Feb; 36(2):214-8. PubMed ID: 420210
[TBL] [Abstract][Full Text] [Related]
55. [Measurement of prothrombin fragment F1+2 for monitoring the anticoagulant effect of phenprocoumon].
Bruhn HD; Zurborn KH
Dtsch Med Wochenschr; 1993 Jul; 118(26):967-70. PubMed ID: 8519230
[TBL] [Abstract][Full Text] [Related]
56. [Is the assessment of prothrombin fragment F1+2 for monitoring of heparin therapy in patients with deep vein thrombosis useful?].
Korte W; Corbetta C; Schmid L
Schweiz Med Wochenschr; 1995 Mar; 125(9):420-3. PubMed ID: 7892570
[TBL] [Abstract][Full Text] [Related]
57. The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment.
Walenga JM; Hoppensteadt D; Pifarré R; Fox NL; Forman S; Hunninghake DB; Campeau L; Herd JA; Hoogwerf BJ; Hickey A; Probstfield JL; Terrin ML
J Thromb Thrombolysis; 2001 Apr; 11(2):143-9. PubMed ID: 11406729
[TBL] [Abstract][Full Text] [Related]
58. Parameters of haemostasis during acute venous thrombosis.
Reiter W; Ehrensberger H; Steinbrückner B; Keller F
Thromb Haemost; 1995 Aug; 74(2):596-601. PubMed ID: 8584990
[TBL] [Abstract][Full Text] [Related]
59. Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin.
Holm J; Hillarp A; Erhardt L; Berntorp E
Thromb Res; 1999 Nov; 96(3):205-12. PubMed ID: 10588463
[TBL] [Abstract][Full Text] [Related]
60. Enhanced thrombin regulation during warfarin therapy in children compared to adults.
Massicotte P; Leaker M; Marzinotto V; Adams M; Freedom R; Williams W; Vegh P; Berry L; Shah B; Andrew M
Thromb Haemost; 1998 Oct; 80(4):570-4. PubMed ID: 9798971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
